Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
There is evidence for a specific impairment of human vigilance following enhancement of serotonergic activity by antidepressant drugs. In the present study, we investigated the putative role of serotonergic–dopaminergic interactions in diminished vigilance by comparing the attentional effects of sertraline, a selective serotonin reuptake inhibitor (SSRI) with additional mild dopamine stimulating effects, with those of paroxetine, a SSRI without dopamine activity, using a placebo-controlled, double-blind, three-way cross-over design. Twenty-one (of 24) healthy middle-aged subjects completed the three treatment periods of 2 weeks in which sertraline (50 mg, days 1–7; 100 mg, days 8–14), paroxetine (20 mg, days 1–7; 40 mg, days 8–14) and placebo were administered. Vigilance (Mackworth Clock Test), selective (Stroop, Dichotic Listening) and divided attention (Dichotic Listening) were assessed at baseline and on days 7 and 14 of each treatment period. Selective and divided attention were unaffected by SSRI treatment. Subchronic administration of paroxetine impaired vigilance performance at each investigated dose. Sertraline did not produce a significant decline in vigilance performance, presumably due to its concomitant effects on dopamine activity, counteracting the negative effects of serotonin on dopamine neurotransmission. It is concluded that a serotonergically mediated reduction of dopamine activity plays an important role in the reduction of human vigilance following SSRI administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cognitive neuroscience of sustained attention: where top-down meets bottom-up.
Sarter, M., Givens, B., & Bruno, J. P. (2001) · Brain Research Reviews · doi:10.1016/s0165-0173(01)00044-3 · Cited by 1,194
Pharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)
Hyttel, J. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199403001-00004 · Cited by 492 · cited 1×
“The in-vitro affinity of paroxetine for muscarinic receptors is approximately six-fold higher than that of sertraline (Hyttel, 1994).”
The Neuropsychology of Attention
Cohen, R. A. (2014) · doi:10.1007/978-0-387-72639-7 · Cited by 332
Schmitt, J. A. J., Jorissen, B. L., Sobczak, S., van Boxtel, M. P. J., Hogervorst, E., Deutz, N. E. P., & Riedel, W. J. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400102 · Cited by 227
Self-citationSynaptic Effects of Antidepressants
RICHELSON, E. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199606002-00001 · Cited by 120 · cited 2×
“Venlafaxine, in addition to its 5-HT promoting effects, also potently stimulates noradrenegic neurotransmission (Richelson, 1996), but this did not prevent a reduction of vigilance performance due to the 5-HT stimulating actions of venlafaxine (O’Hanlon et al.”
BackgroundRamaekers, J., Muntjewerff, N., & O'Hanlon, J. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04468.x · Cited by 103
Self-citationRobbe, H. (1995) · European Neuropsychopharmacology · doi:10.1016/0924-977x(94)00130-4 · Cited by 91
Servan-Schreiber, D., Carter, C. S., Bruno, R. M., & Cohen, J. D. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00449-6 · Cited by 88
Research works printed but not linked: 39
- 10.1093/sleep/14.6.534 · DOI · Paper page
- 10.1016/0024-3205(93)90194-8 · DOI · Paper page
- 10.1097/00004714-199812000-00005 · DOI · Paper page
- 10.1177/106002809703101208 · DOI
- 10.1016/S0166-4328(05)80275-X · DOI
- 10.1016/S0361-9230(98)00054-9 · DOI
- 10.2165/00003495-199957040-00005 · DOI · Paper page
- 10.1177/0269881198012003031 · DOI · Paper page
- 10.1007/s002130050610 · DOI
- 10.1097/00004850-199701000-00002 · DOI
- 10.1007/BF00609258 · DOI
- 10.2165/00023210-200014050-00004 · doi:10.2165/00023210-200014050-00004
- Kahneman D, 1973, Attention and effort
- 10.1176/ajp.153.4.466 · DOI · Paper page
- 10.1007/BF00444684 · DOI
- 10.1007/BF02257400 · DOI · Paper page
- Lane R M, 1999, Ger J Psychiatry, 2, 1
- 10.1007/BF02246413 · DOI
- Mackworth N H, 1961, Selected papers on human factors in the design and use of control systems, 174
- Mattila M J, 1988, J Clin Psychiatry, 49, 52
- 10.1037/0735-7044.111.3.646 · doi:10.1037/0735-7044.111.3.646 · Paper page
- 10.1016/B978-0-12-761050-4.50010-6 · DOI
- Mulder-Hajonides-van-der-Meulen W R E H, Measurement of subjective sleep quality International European Sleep Conference
- 10.1016/0028-3908(90)90101-V · DOI
- 10.1097/00004714-199806000-00006 · DOI · Paper page
- 10.1016/0001-6918(81)90033-0 · DOI · Paper page
- 10.1159/000026676 · DOI · Paper page
- 10.1016/0013-4694(95)00124-H · DOI
- 10.1097/00004714-199606002-00002 · doi:10.1097/00004714-199606002-00002
- 10.1002/(SICI)1099-1077(1998110)13:2+<S49::AID-HUP49>3.0.CO;2-1 · DOI
- Robbins T, 1995, The cognitive neurosciences, 703
- 10.1017/S0033291700003032 · DOI · Paper page
- 10.1016/S0301-0511(96)05222-2 · DOI · Paper page
- Saletu B, 1988, J Clin Psychiatry, 49, 59
- Sanders AF, 1998, Elements of human performance, 394
- Servan-Schreiber D, 1998, D-Amphetamine effects in human subjects performing a selective attention task. Biol Psychiatry, 43, 723
- Stahl S M, 1998, J Clin Psychiatry, 59, 5
- 10.1037/h0054651 · DOI · Paper page
- 10.1001/archpsyc.1965.01720310065008 · DOI · Paper page
Cited by
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
Chaudhuri, K. R., & Schapira, A. H. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70068-7 · Cited by 1,738
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
The bright side of being blue: depression as an adaptation for analyzing complex problems.
Andrews, P. W., & Thomson, J. A. (2009) · Psychological Review · doi:10.1037/a0016242 · Cited by 549
Effects of tryptophan loading on human cognition, mood, and sleep
Silber, B. Y., & Schmitt, J. A. J. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.08.005 · Cited by 260
“Previous research has shown that modulations to serotonergic activity through administration of SSRIs induce an acute and steady increase in pupil diameter (Schmitt et al., 2002), independently invoking CFF threshold increases.”
BackgroundSelf-citationPrado, C. E., Watt, S., & Crowe, S. F. (2018) · Neuropsychology Review · doi:10.1007/s11065-018-9369-5 · Cited by 188
Metadata
- Authors
- Schmitt, J. A. J., Ramaekers, J. G., Kruizinga, M. J., van Boxtel, M. P. J., Vuurman, E. F. P. M., & Riedel, W. J.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2002-05
- Volume
- 16
- Issue
- 3
- Pages
- 207-214
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W1969400636
- Cited by
- 69
- References
- 9
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. https://app.cochat.ai/papers/10.1177/026988110201600303
- The paper
- Schmitt, J. A. J., Ramaekers, J. G., Kruizinga, M. J., van Boxtel, M. P. J., Vuurman, E. F. P. M., & Riedel, W. J. (2002). Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. Journal of Psychopharmacology. https://doi.org/10.1177/026988110201600303
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.